^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4: 217—241.doi:10.1016/S1574-1400(08)00012-1.
^Villalobos-Molina, R; Ibarra, M; Hong, E (1995). „The 5-HT2 receptor antagonist, pelanserin, inhibits alpha 1-adrenoceptor-mediated vasoconstriction in vitro”.European Journal of Pharmacology.277 (2–3): 181—5.PMID7493607.doi:10.1016/0014-2999(95)00074-u.
^Hayao, Shin; Havera, Herbert J.; Strycker, Wallace G.; Leipzig, T. J.; Kulp, Richard A.; Hartzler, Harold E. (1965). „New Sedative and Hypotensive 3-Substituted 2,4(1H,3H)-Quinazolinediones”.Journal of Medicinal Chemistry.8 (6): 807—811.PMID5885076.doi:10.1021/jm00330a017.
^Havera, Herbert J. (1979). „Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents”.Journal of Medicinal Chemistry.22 (12): 1548—1550.doi:10.1021/jm00198a024.
^Garcia, J. D.; Somanathan, R.; Rivero, I. A.; Aguirre, G.; Hellberg, L. H. (2000). „Synthesis of Deuterium-Labeled Antihypertensive 3-(4-Phenyl-1′-Piperazinyl)-Propyl-2,4-Quinazolinedione”.Synthetic Communications.30 (15): 2707—2711.doi:10.1080/00397910008086895.
^Li, Xin; Lee, Yong-Rok; Kim, Sung-Hong (2011). „Concise Synthesis of Pelanserine, Goshuyuamide II, and Wuchuyuamide II with Quinazolinedione Nuclei”.Bulletin of the Korean Chemical Society.32 (9): 3480—3482.doi:10.5012/bkcs.2011.32.9.3480.
^Cortez, R.; Rivero, I. A.; Somanathan, R.; Aguirre, G.; Ramirez, F.; Hong, E. (1991). „Synthesis of Quinazolinedione Using Triphosgene”.Synthetic Communications.21 (2): 285—292.doi:10.1080/00397919108020823.
^AT 269143B, "Verfahren zur Herstellung von neuen Chinazolindionderivaten und ihrer Säureadditionssalze bzw. ihrer entsprechenden Piperaziniumverbindungen [Process for the preparation of new quinazolinedione derivatives and their acid addition salts or their corresponding piperazinium compounds]", published 1969-03-10, assigned toMiles Laboratories, Inc.